Tags: diabetes | drug | heart | risks | Type | 2 | canagliflozin

New Diabetes Drug Carries Heart Risk

Tuesday, 08 Jan 2013 12:03 PM


Johnson & Johnson (JNJ)’s experimental diabetes drug canagliflozin may have heart risks, U.S. regulators said.
Studies for the drug, which J&J has proposed calling Invokana for adults with Type 2 diabetes, showed higher risk of cardiovascular events in the first 30 days in those taking the pill, Food and Drug Administration staff said today in a report ahead of a Jan. 10 meeting of advisers.
The once-a-day-pill, which expels sugar in the urine after it’s filtered out of the blood by the kidneys, is J&J’s effort to be the first to market with a new class of diabetes treatments known as SGLT2 inhibitors.
Copyright Bloomberg News



© HealthDay

   
1Like our page
2Share
Health-News
An experimental drug to treat Type 2 diabetes called canagliflozin may have heart risks, says the FDA.
diabetes,drug,heart,risks,Type,2,canagliflozin,cardiovascular,events
106
2013-03-08
Tuesday, 08 Jan 2013 12:03 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved